Adagene Presents Results at ESMO Congress that Show Best-in-Class Therapeutic Potential for Anti-CTLA-4 SAFEbody® ADG126 ( Muzastotug ) in Combination with KEYTRUDA® ( Pembrolizumab ) in Advanced/Metastatic Microsatellite-stable ( MSS ) Colorectal Cancer ( CRC ) - Adagene ( NASDAQ:ADAG )
- Confirmed partial responses ( PRs ) doubled to four since ASCO GI in MSS CRC patients without liver and peritoneal metastases for overall response rate ( ORR ) of 24% ( 4/17 ) with ADG126 10 mg/kg every three weeks ( Q3W ) in combination with pembrolizumab -
| Ticker |
Sentiment |
Impact |
|
OPTGF
|
Neutral
|
2 %
|
|
GLP
|
Neutral
|
2 %
|
|
ADAG
|
Somewhat Bullish
|
21 %
|
